论文部分内容阅读
以短期和长期服用氯丙嗪的精神分裂症病人为对象，比较合并安坦后两组氯丙嗪血药浓度变化的差异。根据以往连续服用氯丙嗪≤１年或≥５年，将样本分为短期服药组（１７例）和长期服药组（２１例），给予口服安坦４ｍｇ／日，分别于合并安坦前、合并后２周、４周测定氯丙嗪血药浓度。结果发现短期服药组氯丙嗪血药浓度有显著下降（Ｆ＝４．０７，Ｐ＜０．０５），长期服药组无显著下降（Ｐ＞０．０５）。在降低幅度＞２０％的病例中，短、长期服药组分别占４１．２％和９．５％（χ２＝５．６１，Ｐ＜０．０１）。相关分析结果，氯丙嗪血药浓度下降幅度与以往服药期呈显著负相关。可见安坦降低氯丙嗪血药浓度的作用仅在以往服药期较短或部分急性病人当中显得较为明显，而长期服药病人合并安坦后氯丙嗪血药浓度无显著变化
Short-term and long-term use of chlorpromazine in patients with schizophrenia as the object, compare the two groups after the merger of chlorpromazine plasma concentration changes. According to the past continuous use of chlorpromazine ≤ 1 year or ≥ 5 years, the samples were divided into short-term medication group (17 cases) and long-term medication group (21 cases), given oral Antan 4mg / day, Serum concentrations of chlorpromazine were measured at 2 weeks and 4 weeks after the combination. The results showed that short-term plasma chlorpromazine drug concentration decreased significantly (F = 4.07, P <0.05), long-term medication group no significant decline (P> 0.05). Short-term and long-term medication accounted for 41.2% and 9.5%, respectively (χ2 = 5.61, P <0.01) in the case of> 20% reduction. Correlation analysis showed that the decrease of plasma concentration of chlorpromazine was negatively correlated with the previous medication. It can be seen that Antain’s effect of lowering the plasma concentration of chlorpromazine is only obvious in the short or some acute patients in the past, while there is no significant change in the plasma concentration of Azathine after long-term administration